Alnylam Adds New Program to Pipeline as It Shelves Anemia Candidate | GenomeWeb

Alnylam Pharmaceuticals this week provided an update to its research and development activities, adding a new preclinical program to its pipeline with ALN-AS1 for acute intermittent porphyria while dropping its refractory anemia drug ALN-HPN in order to focus on “higher priority” efforts.

Notably, the ALN-AS1 program will take advantage of Alnylam's GalNAc conjugate liver-delivery strategy, reflecting the company's growing focus on conjugates, which CEO John Maraganore described in 2011 as “the future for delivery of small interfering RNAs.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.